Skip to main content
. Author manuscript; available in PMC: 2016 Dec 13.
Published in final edited form as: Cancer Gene Ther. 2016 Apr 15;23(5):142–148. doi: 10.1038/cgt.2016.14

Figure 5. IP CAR-Ts in combination with suppressor cell targeting for in vivo treatment.

Figure 5

IP CAR-Ts combined with depleting antibodies against MDSC and Treg, or blocking antibodies against the PD-L1 pathway, were administered to mice injected with MC38CEA-luc. Tumor reduction was monitored by bioluminescence over 14 days. Bar graphs compare the efficacy of regional IP CAR-Ts to systemic TV CAR-Ts, and IP CAR-Ts alone to IP CAR-Ts with antibodies on day 8 after the treatments (A) and at the end of the study on day 14 (B). Bars are representative of 4 animals per group. Black arrows represent CAR-T treatments. Symbols denoting significance appear for specific days below the x axis (C). Gross inspection images, as well as bioluminescence images, are shown for all groups on day 14 (D). Error bars are representative of SEM values. P values were calculated using Student’s t test.